“Retatrutide is safer than tirzepatide.”
What the evidence shows
Retatrutide is an investigational triple-hormone agonist with striking weight-loss results in an early (phase 2) trial. It is not approved by the FDA, and there has been no head-to-head trial comparing its safety to tirzepatide.
What we still don’t know
Long-term safety, rare adverse events, and any comparative safety versus tirzepatide are simply unknown. Larger, longer phase 3 trials are still underway.
Why the claim misleads
A comparative-safety claim needs head-to-head, long-term data that does not yet exist. Calling an unapproved drug "safer" than an approved one inverts what the evidence can support — and this exact framing is often used to steer people toward grey-market sources. Because it isn't approved, anything sold to consumers as "retatrutide" today comes from unregulated sources, and there is no way to verify what is actually in the vial.
Graded by The Peptide Era · evidence, not hype